| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| margetuximab | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Malignant neoplasm of breast[MeSHID:D001943] Neoplasm Metastasis[MeSHID:D009362] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] Adenocarcinoma[MeSHID:D000230] |
1.5 | approved | unknown |
| margetuximab | receptor tyrosine-protein kinase erbb-2 | biotech | NA | drugbank , DGIDB | Malignant neoplasm of breast[MeSHID:D001943] Neoplasm Metastasis[MeSHID:D009362] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] Adenocarcinoma[MeSHID:D000230] |
1.5 | approved,investigational | antagonist,antibody |
| margetuximab | receptor tyrosine-protein kinase erbb-2 | biotech | NA | drugbank , DGIDB | Malignant neoplasm of breast[MeSHID:D001943] Neoplasm Metastasis[MeSHID:D009362] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] Adenocarcinoma[MeSHID:D000230] |
1.5 | approved,investigational | antagonist,inhibitor |
| margetuximab | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Malignant neoplasm of breast[MeSHID:D001943] Neoplasm Metastasis[MeSHID:D009362] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] Adenocarcinoma[MeSHID:D000230] |
1.5 | approved | antibody |
| margetuximab | erbb2 tyrosine kinase receptor | NA | Successful target | TTD , DGIDB | Malignant neoplasm of breast[MeSHID:D001943] Neoplasm Metastasis[MeSHID:D009362] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] Adenocarcinoma[MeSHID:D000230] |
1.5 | approved | inhibitor |
| margetuximab | receptor tyrosine-protein kinase erbb-2 | biotech | NA | drugbank , DGIDB | Malignant neoplasm of breast[MeSHID:D001943] Neoplasm Metastasis[MeSHID:D009362] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Stomach[MeSHID:D013270] Malignant neoplasm of gastrointestinal tract[MeSHID:D005770] Adenocarcinoma[MeSHID:D000230] |
1.5 | approved,investigational | antagonist |
| click here to return to the previous page | ||||||||